One recent study shows BRCA2 deletion triggers TERRA hyperexpression and alternative lengthening mechanisms (ALT) in colon cancer in presence of telomerase activity, which opens the question if patients bearing BRCA2 mutation suitable for anti-telomerase therapies (Pompili et al., 2019). The gene discussed is BRCA2; the disease is malignant colon neoplasm.